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ABSTRACT
Stem cell transplantation (SCT) is associated with complications that may necessitate intensive care unit (ICU)
admission. The outcome for SCT patients requiring ICU admission has been reported to be poor. We describe
the outcome of consecutive SCT patients admitted to the ICU at a single center. The study was a retrospective
review of all patients at the Queen Elizabeth II Health Sciences Center who received an SCT between 1992
and 2001 and were subsequently admitted to the ICU. The primary outcome was overall survival at 12 months
after ICU admission. There were 440 SCTs in the study period; 38 of these patients were admitted to the ICU
on 42 separate occasions. The primary indication for ICU admission was respiratory failure. The probability
of survival at 12 months was 21.6% (95% CI, 8.4%-34.9%). On multivariate analysis, the only statistically
significant variable associated with decreased 12-month survival was vasopressor use. The probability of
survival for patients receiving vasopressor support was 5% (95% CI, 0%-14.5%) at 30 days and 0% at 12
months, whereas the probability of survival for patients not receiving vasopressor support was 76.5% (95% CI,
56.3%-96.6%) at 30 days and 45.8% (95% CI, 21.5%-69.9%) at 12 months. In this 10-year review of
consecutive SCT recipients requiring ICU admission, we found that the outcome of SCT patients requiring
ICU admission may not be as poor as previously reported. However, SCT recipients requiring vasopressor
support had very poor outcomes. These findings will be important in deciding which SCT patients may benefit
from ICU admission and care.
© 2006 American Society for Blood and Marrow Transplantation
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fNTRODUCTION
Stem cell transplantation (SCT) is a standard treat-
ent for many hematologic malignancies. Although
t offers the potential for cure in several malignancies,
ts use is limited because of signiﬁcant morbidity and
ortality due to organ toxicity. Frequent complica-
ions after transplantation include pulmonary toxici-
ies, veno-occlusive disease, infection, graft-versus-host
isease, gastrointestinal hemorrhage, and hepatic and
enal failure [1].
Because of the serious nature of these complications,
atients undergoing SCT may require admission to the
ntensive care unit (ICU). In previously reported stud-
es, the frequency of SCT patients requiring ICU
dmission after transplantation has varied widely, with
eported admission rates between 7% and 40% [2-13]. h
B&MTThe outcome for SCT patients admitted to the
CU is generally considered to be poor. Several pre-
ious studies have investigated outcomes for these
atients and have described predictors of mortality, in-
luding the need for mechanical ventilation, the need
or hemodynamic support, organ failure, and higher
cute Physiology, Age, and Chronic Health Evalua-
ion II scores. Because of the signiﬁcant ﬁnancial costs
nd emotional burdens associated with ICU care, there
s an increasing focus on the ability to provide prog-
ostic information to clinicians, patients, and families
bout which patients are most likely to beneﬁt from
CU care.
In previous studies, survival rates and length of
ollow-up have been highly variable; some studies
ave reported data on patients only until ICU dis-
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3harge. Most studies have found the lowest survival in
atients requiring mechanical ventilation. In the larg-
st retrospective study of mechanically ventilated SCT
atients, Rubenfeld and Crawford [2] reported a sur-
ival of only 6.1% at 30 days in this subgroup.
We performed a retrospective study to describe
he outcome of SCT patients admitted to the ICU
t our center and to evaluate the frequency of admis-
ion, outcomes, and predictors of survival. Our study
ncludes 10 years of consecutive patients at a single
enter with a follow-up of 12 months. Our results
rovide rational information for clinicians for deci-
ions regarding the utility of ICU care in the SCT
opulation.
ATERIALS AND METHODS
All patients at the Queen Elizabeth II Health Sci-
nces Centre who received an SCT between January
992 and December 2001 and who required ICU care
uring that admission were included in the study. The
tudy was approved by the institutional ethics com-
ittee. For patients with more than 1 ICU admission,
nly the ﬁrst admission during the study period was
sed for analysis. Patients were identiﬁed through the
CT database and health records department at our
nstitution. Baseline demographic data including age,
ex, underlying disease, conditioning regimen, and
ype of transplant (autologous, sibling allogeneic, or
atched unrelated) were determined. The following
ariables were also ascertained: indications for ICU
dmission, length of ICU stay, use and duration of
echanical ventilation, use and duration of vasopres-
ors, hepatic function, renal function, presence of graft-
ersus-host disease (GVHD), survival at 30 days after
ischarge from the ICU, and survival at 12 months.
Indications for ICU admission were categorized as
ollows: respiratory failure requiring mechanical ven-
ilation, hemodynamic instability requiring aggressive
onitoring and/or hemodynamic support, or a com-
ination of respiratory failure and hemodynamic in-
tability. Use of mechanical ventilation was deﬁned as
ny use of endotracheal intubation and assisted venti-
ation; if the duration was 24 hours but 6 hours, it
as considered as 1 day for the purpose of analysis.
asopressor use was deﬁned as any use of phenyleph-
ine, norepinephrine, or dopamine at 3 g/kg/min.
epatic function was based on total bilirubin. Values
ere collected at baseline and at the peak bilirubin
evel during ICU admission. Renal function was based
n calculated creatinine clearance by using ideal body
eight and was determined at baseline and at peak
reatinine during ICU admission. GVHD was classi-
ed by using standard criteria [14].
All statistical analysis was performed by using SAS
version 8.0; SAS Institute, Cary, NC). All variables
02ere summarized by using descriptive statistics. The
rimary outcome was survival at 12 months. The 30-
ay and 12-month survival were determined by the
aplan-Meier estimator. Signiﬁcance was determined
y using the log-rank method. Cox proportional haz-
rd regression models were used to examine the rela-
ionship of variables to survival.
ESULTS
There were 440 SCTs performed during the study
eriod. Thirty-eight patients were admitted to the
CU on 42 separate occasions. Two patients were
dmitted to the ICU twice, and 1 had 3 admissions.
nly the ﬁrst admission was used for analysis. The
verall incidence of ICU admission was 8.6%. One
hart was unavailable for review; thus, 37 patients with
n initial ICU admission after transplantation were
nalyzed. Table 1 summarizes the baseline character-
stics of the patients.
The primary reason for ICU admission was respi-
atory failure necessitating assisted ventilation. There
ere 14 patients (38%) admitted with a primary re-
piratory problem; the etiology of respiratory failure
as variable and included infection (5 patients), severe
ucositis (3 patients), pulmonary hemorrhage (2 pa-
ients), acute respiratory distress syndrome (2 pa-
ients), anaphylaxis (1 patient), and sleep apnea (1
atient). Eleven patients (30%) were admitted for he-
able 1. Patient Characteristics (n  37)
Variable Date
ge (y)
Median 42
Range 17-66
ex, n (%)
Male 20 (54)
Female 17 (46)
nderlying disease, n (%)
Non-Hodgkin lymphoma 11 (30)
Acute myeloid leukemia 8 (22)
Multiple myeloma 5 (13)
Chronic myeloid leukemia 4 (11)
Myelodysplastic syndrome 3 (8)
Acute lymphoblastic leukemia 2 (5)
Aplastic anemia 2 (5)
Hodgkin lymphoma 1 (3)
Breast cancer 1 (3)
ype of transplant, n (%)
Allogeneic
Sibling 22 (60)
Matched unrelated 6 (16)
Autologous 9 (24)
VHD, n (%)
Absent 32 (86)
Present 5 (14)
ndications for ICU admission, n (%)
Respiratory failure 14 (38)
Hemodynamic instability 11 (30)
Both 10 (27)
Other 2 (5)
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Bodynamic instability necessitating monitoring or
upport. Ten patients (27%) were admitted with both
espiratory failure and hemodynamic instability. Two
atients (5%) were admitted after surgery. The ﬁrst
nderwent total colectomy, splenectomy, cholecystec-
omy, and liver biopsy for GVHD. The second patient
nderwent right anterior thoracotomy and wedge re-
ection for aspergillosis. The median length of stay in
CU was 4 days (range, 1-25 days).
The overall survival at 30 days after discharge
rom the ICU was 37.8% (95% CI, 22.2%-53.5%).
he overall survival at 12 months was 21.6% (95%
I, 8.4%-34.9%; Figure 1). In comparison, the 12-
onth survival of the 402 SCT recipients who were
ot admitted to the ICU was 72.2% (95% CI, 66.7%-
6.9%). None of the 6 matched unrelated donor
ransplant recipients survived, whereas 4 (18.2%) of
2 sibling allogeneic transplant recipients survived
nd 4 (44.4%) of 9 autologous transplant recipients
urvived at 12 months. Causes of death are listed in
able 2. The most common cause of death was mul-
iorgan failure, deﬁned as severe dysfunction in 3
rgan systems. The second most common cause of
lavivru
S
0 100
0.1
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2.0
0.0
Figure 1. Survival of SCT
able 2. Causes of Death (n  29)
Cause of Death n (%)
ultiorgan failure 10 (34)
cute respiratory distress syndrome 4 (14)
epsis 4 (14)
andidiasis 2 (7)
spergillosis 2 (7)
epatic failure 2 (7)
ncephalitis 1 (3)
astrointestinal bleed 1 (3)
troke 1 (3)e
nknown 2 (7)
B&MTeath was infection: either bacterial sepsis or dissem-
nated fungal infection.
Of all patients admitted to the ICU, 25 (68%) of
7 required mechanical ventilation. The median du-
ation of mechanical ventilation was 5 days (range,
-25 days). Sixty-two percent (5/8) of the survivors
nd 69% (20/29) of nonsurvivors required mechanical
entilation. Three of 6 of the matched unrelated do-
or transplant recipients, 16 of 22 sibling allogeneic
ransplant recipients, and 6 of 9 autologous transplant
ecipients required mechanical ventilation.
There were 5 (13%) of 37 patients with GVHD at
he time of ICU admission. Three patients had a
istologically conﬁrmed diagnosis, and 2 patients were
iagnosed according to clinical presentation. All pa-
ients with GVHD were receiving treatment with ste-
oids. One patient with GVHD survived.
In multivariate analysis, neither the use of me-
hanical ventilation nor pre-ICU patient characteris-
ics were found to affect survival. The only variable
hat was predictive of decreased survival was the re-
uirement for vasopressor support during the ICU
dmission (P  .001). The number of patients who
equired vasopressor support was 20 (54%) of 37, and
he median duration of vasopressor use was 3 days
range, 1-18 days). The probability of survival for
atients receiving vasopressor support was 5% (95%
I, 0%-14.5%) at 30 days and 0% at 12 months. For
atients who did not require vasopressor support, the
robability of survival was 76.5% (95% CI, 56.3%-
6.6%) at 30 days and 45.8% (95% CI, 21.5%-69.9%)
t 12 months. This difference was signiﬁcant with a
azard ratio of 6.54 (95% CI, 2.62-16.34). Figure 2
hows survival stratiﬁed for vasopressor use. Three of
of the matched unrelated donor transplant recipi-
ays)
200 300
nts admitted to the ICU.Time (dnts, 13 of 22 sibling allogeneic transplant recipients,
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3nd 4 of 9 autologous transplant recipients required
asopressors.
The length of ICU stay, the year of ICU admis-
ion, impaired hepatic function, and the presence of
VHD were not found to affect survival. There was a
rend toward decreased survival with decreased creat-
nine clearance, but this was not statistically signiﬁ-
ant.
ISCUSSION
SCT is widely offered as a treatment for many
ematologic malignancies. Despite advances in condi-
ioning regimens and supportive care, SCT is still
ssociated with a signiﬁcant risk of morbidity and
ortality.
In previous studies, the frequency of admission to
he ICU after SCT has varied, with admission rates
rom 7% to 40% [2-13]. In our study, the frequency of
CU admission was only 8.6%. There are several
ossible explanations for the relatively low admission
ate. In our SCT unit, we are able to provide 1-to-1
ursing care. At our center, ICU admission is primar-
ly based on the need for either mechanical ventilation
r vasopressor support. These relatively stringent se-
ection criteria may contribute to low admission rates.
ow admission frequency may also reﬂect selection of
atients who are most likely to beneﬁt from ICU care.
The survival of SCT patients admitted to the ICU
as also varied in previous reviews. The Seattle group
eported 3 large series of mechanically ventilated post-
CT patients. Crawford and Peterson [3] reported
nly 3% survival at 6 months among 348 mechanically
lavivru
S
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Figure 2. Survival of SCT recipiententilated patients. In a previous study, their group 8
04ound 13% survival at 30 days and 6.9% survival at
100 days [4]. In a nested case-control study, Ruben-
eld and Crawford [2] found 6.1% survival for me-
hanically ventilated patients, and only 3.5% survived
or 1 year. They found no survivors among venti-
ated patients with lung injury and either hepatic and
enal insufﬁciency or hemodynamic instability neces-
itating vasopressors. Three other studies were also
peciﬁc to mechanical ventilation. Survival rates in 2
tudies were low, with 6-month survival rates of 3%
nd 5% [5,6]. Scott et al. [7] found comparatively
etter survival at 6 months of 12%.
Several other studies have included all SCT recip-
ents admitted to the ICU, including both ventilated
nd nonventilated patients. In the largest study of 116
atients, Jackson et al. [8] found 23% survival to hos-
ital discharge with 14% long-term survival at a mean
ollow-up of 4.2 years. Although the requirement for
echanical ventilation was associated with decreased
urvival in univariate analysis, it did not remain sig-
iﬁcant in multivariate analysis. The year of ICU
dmission, the need for hemodynamic support, and
ncreased serum bilirubin were all associated with de-
reased survival in multivariate analysis. Paz et al. [9]
ound 33% survival to ICU discharge, but longer
ollow-up data were not reported. They found me-
hanical ventilation to be a signiﬁcant predictor of
ortality, with only 1 mechanically ventilated patient
ischarged from the ICU. The development of mul-
iorgan failure and higher Acute Physiology, Age, and
hronic Health Evaluation II scores were also associ-
ted with decreased survival. Afessa et al. [10] found
n-hospital mortality for nonsurgical SCT patients of
(days)
200 300
No Vasopressor
Vasopressor
Log-Rank Test p= < 0.001
ted to the ICU, by vasopressor use.Time 7% with 93% mortality for those requiring mechan-
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Bcal ventilation. In their study, vasopressor use was not
redictive of mortality. Denardo et al. [11] found 17%
urvival to hospital discharge but only 3.8% survival at
year. Mechanical ventilation was associated with a
orse outcome. Torrecilla et al. [12] found 12% sur-
ival to hospital discharge; multiorgan failure, septic
hock, and mechanical ventilation were all associated
ith a worse outcome. Finally, Price et al. [13] con-
ucted a prospective study on 115 consecutive trans-
lant patients admitted to the ICU; overall survival
as 46.1%, but survival was only 18.8% for mechan-
cally ventilated patients.
Most, but not all, of the previous studies found
hat the requirement for mechanical ventilation was
ssociated with increased mortality. In contrast, me-
hanical ventilation was not found to be predictive of
ortality in our study. There are several possible
easons for this ﬁnding. First, the total number of
atients in our study was relatively small, and, thus,
he study may not have the power to detect small
ifferences. Second, our results may reﬂect the selec-
ion of patients who would potentially beneﬁt most
rom mechanical ventilation, and this intervention
ay not have been offered in futile situations.
We found a statistically signiﬁcant difference in
ortality in patients who required vasopressor sup-
ort. None of the patients who required vasopressors
urvived to 12 months. Vasopressors may be consid-
red a marker for severity of illness in this patient
opulation. Of the previously reported studies, some
ound requirements for vasopressors to be associated
ith decreased survival [2,8], whereas others did not
10], and many did not speciﬁcally analyze the use of
asopressors as a variable. Although vasopressor use
ay be a useful tool to predict outcome, it has limi-
ations, because there is signiﬁcant variability in prac-
ice both among institutions and among intensivists in
asopressor use.
There are several limitations in this study. As a
etrospective study, there were no set criteria for ICU
dmission, and there may have been considerable vari-
bility among SCT physicians in considering ICU
eferrals and among intensivists in accepting SCT
atients for ICU admission. This study included only
CT patients who were admitted to the ICU and did
ot compare outcomes with the 402 SCT patients not
dmitted to the ICU during the study period.
Our data strongly suggest that survival after ICU
dmission is not as poor as previously described. Over
10-year period at our institution, ICU care was
ssociated with a 37.8% 30-day survival and a 21.6%
2-month survival in SCT patients. This afﬁrms the
ppropriateness of intensive care for this patient pop-
lation. In contrast to other studies, we did not ﬁnd an
ssociation between mechanical ventilation and sur-
ival. In this series, the use of vasopressors was a
trong predictor of poor survival, and this observation
B&MTay be useful to provide prognostic information to
linicians, patients, and their families.
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